The aim of this study was to evaluate the water consumption during an interventional program using glucagon like peptide 1 receptor analog (aGLP1) or inhibitors of sodium glucose-cotransporter2 (iSGLT2) medication at type 2 diabetes mellitus (T2DM) patients. This was a retrospective study during the year 2023, using data from multiple centers. We included 45 T2DM patients (23women and 22men), age (mean±standard deviation) 61,12±6,13years, duration of T2DM 5,16±1,41years, BMI=34,4±3,15kg/m2, HbA1c=7,20±0,2%, divided in 3 similar lots (p>0.05). All these groups were matched according to all important characteristics at the beginning. All patients were initially treated with metformin (met) 2g/day. After first evaluation we consider: lot A received iSGLT2 plus met, lot B received aGLP1 plus met and lot C with met. All patients received 10%calories reduction program in normal conditions. Targets were established using ADA23 guidelines. Observational parameters at baseline and after 1 and 3 months included water consumption (WaCo) liter/day, estimation in a 3 day-journal. Initially and in the end were determinate HbA1c and BMI. In our study it seems to be a significant clinical difference during a regular losing weight program considering water consumption (p>0,05). Significant differences were observed comparing lot A vs. lot B and lot A vs. lot C when we kept the different antidiabetic medication used during this program (p<0,05).
C. Constantin: None. G. Constantin: None. S.M. Lulia: None. A.M. Ijacu: None. M. Dragoicea: None. C. Zugravu: None. L.G. Gagiu: None.
Research Metabolism Center - Romania
